Ultragenyx To Present Setrusumab Update At ASBMR 2023 Including New Data From Phase 2/3 Orbit Study In Osteogenesis Imperfecta
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Mereo BioPharma Group plc (NASDAQ:MREO) will present new data from the Phase 2/3 Orbit study of setrusumab in osteogenesis imperfecta (OI) at the American Society for Bone and Mineral Research 2023 Annual Meeting. The data includes updated results on annualized clinical fracture rate in patients aged 5 to <26 years, and data on the burden of fractures for individuals living with OI. The companies previously announced positive data from the dose-selection Phase 2 portion of the Orbit study showing that setrusumab rapidly induced bone production in OI-affected patients.
October 09, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mereo BioPharma's collaboration with Ultragenyx on the development of setrusumab could potentially boost investor confidence in the company's pipeline.
Mereo BioPharma's collaboration with Ultragenyx on the development of setrusumab could potentially boost investor confidence in the company's pipeline. This could lead to increased demand for the company's stock, potentially driving up its price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Ultragenyx's presentation of new data from the Phase 2/3 Orbit study of setrusumab could potentially boost investor confidence in the company's late-stage program.
The presentation of new data from the Phase 2/3 Orbit study of setrusumab could potentially boost investor confidence in Ultragenyx's late-stage program. This could lead to increased demand for the company's stock, potentially driving up its price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100